Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Fractional Dose of Bivalent and Nonavalent HPV Vaccines
NCT04235257Phase 4Active, not recruiting
- Sponsor
- University of Washington
- Start
- Nov 2020
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of human papillomavirus vaccine in human papillomavirus infection (2 arms), sponsored by University of Washington. Primary endpoint: HPV antibody detection after fractional HPV vaccination at 12 months. Started Nov 2020; status: active, not recruiting.
02
Drugs
human papillomavirus vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT04235257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04235257.